Drawing for TS-MICRO

USPTO serial 98395328

TS-MICRO

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SONNEBORN, TRICIA L
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TS-MICRO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
010Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal spaceACTIVE—
041Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 30, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 30, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 18, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 17, 2025EX2GSOU EXTENSION 2 GRANTED—
Aug 17, 2025EXT2SOU EXTENSION 2 FILED—
Aug 17, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 18, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 18, 2025EX1GSOU EXTENSION 1 GRANTED—
Feb 17, 2025EXT1SOU EXTENSION 1 FILED—
Feb 17, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 27, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 2, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 2, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 12, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 29, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 2, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 2, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 2, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 20, 2024DOCKASSIGNED TO EXAMINER—
Mar 20, 2024MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 20, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 7, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance